|Articles|January 19, 2021
Parenteral Subvisible Particle Testing
Author(s)Entegris
This paper details various USP subvisible particulate tests used to assure the minimization of particle counts in intravenous injections and the requirements and technologies used to meet them.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Year in Review: How FDA Guidances Defined the 2025 Biopharma Landscape
2
AI, CRISPR, and mRNA Driving Biotech’s Smartest Decade Yet
3
Conjugation and Regulation Challenges for Advanced Molecules: Part Two of Three with Abzena
4
Top BP Videos of 2025: An Intersection of AI, Innovation, and Compliance
5